FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4232181540> ?p ?o ?g. }

• W4232181540 endingPage "175" @default.
• W4232181540 startingPage "168" @default.
• W4232181540 abstract "Olanzapine, an atypical antipsychotic drug with affinities for dopamine, serotonin, and histamine binding sites appears to be associated with substantial weight gain and metabolic alterations. The aim of this study was to evaluate weight gain and metabolic alterations in rats treated with olanzapine on a hypercaloric diet. We used 40 rats divided into 4 groups: Group 1, standard food and water conditions (control); Group 2, standard diet plus olanzapine; Group 3, cafeteria diet (hypercaloric); and Group 4, olanzapine plus cafeteria diet. Olanzapine was administered by gavage at a dose of 3 mg/kg for 9 weeks. There were no significant changes in the cholesterol levels in any group. Glucose levels increased in Group 3 by the fourth week. Triglyceride levels were altered in group 2 toward the end of the experiment. Leptin levels decreased in Groups 2 and 4. Complex II activity in the muscles and liver was altered in Group 2 (muscle), and Groups 2, 3, and 4 (liver). Complex IV activity was altered only in the liver in Group 2, without significant alterations within the muscles. These results suggest that olanzapine is correlated with weight gain and the risks associated with obesity. A olanzapina, uma droga antipsicótica atípica com afinidade por locais de ligação de dopamina, serotonina e histamina, parece se associar a um ganho de peso e a alterações metabólicas consideráveis. O objetivo desse estudo foi avaliar o ganho de peso e as alterações metabólicas em ratos tratados com olanzapina numa dieta hipercalórica. Usamos 40 ratos divididos em 4 grupos: Grupo 1, condições padrão de alimento e água (controle); Grupo 2, dieta padrão mais olanzapina; Grupo 3, dieta hipercalórica; e Grupo 4, olanzapina mais dieta hipercalórica. Olanzapina foi administrada por gavagem a uma dose de 3 mg/kg por 9 semanas. Não houve alterações significativas nos níveis de colesterol em qualquer um dos grupos. Os níveis de glicose aumentaram no Grupo 3 por volta da quarta semana. Os níveis de triglicerídeos estavam alterados no Grupo 2 ao final do experimento. Os níveis de leptina diminuíram nos Grupos 2 e 4. A atividade do complexo II nos músculos e no fígado se alterou no Grupo 2 (músculos) e nos Grupos 2, 3 e 4 (fígado). A atividade do complexo IV se alterou apenas no fígado no Grupo 2, sem alterações significativas nos músculos. Esses resultados sugerem que olanzapina se correlaciona ao ganho de peso e aos riscos associados à obesidade." @default.
• W4232181540 created "2022-05-12" @default.
• W4232181540 creator A5002947325 @default.
• W4232181540 creator A5007102081 @default.
• W4232181540 creator A5020126544 @default.
• W4232181540 creator A5057091098 @default.
• W4232181540 creator A5061548672 @default.
• W4232181540 creator A5062953785 @default.
• W4232181540 creator A5067659312 @default.
• W4232181540 creator A5068399783 @default.
• W4232181540 creator A5078614945 @default.
• W4232181540 creator A5081439849 @default.
• W4232181540 creator A5085928491 @default.
• W4232181540 creator A5090013116 @default.
• W4232181540 date "2012-06-01" @default.
• W4232181540 modified "2023-10-06" @default.
• W4232181540 title "Energy metabolism, leptin, and biochemical parameters are altered in rats subjected to the chronic administration of olanzapine" @default.
• W4232181540 cites W1547411530 @default.
• W4232181540 cites W1585966888 @default.
• W4232181540 cites W1775749144 @default.
• W4232181540 cites W1963992314 @default.
• W4232181540 cites W1976393800 @default.
• W4232181540 cites W1977097317 @default.
• W4232181540 cites W1983922213 @default.
• W4232181540 cites W1986461592 @default.
• W4232181540 cites W1989544233 @default.
• W4232181540 cites W1994678934 @default.
• W4232181540 cites W1995060015 @default.
• W4232181540 cites W1996664407 @default.
• W4232181540 cites W2006988128 @default.
• W4232181540 cites W2016637416 @default.
• W4232181540 cites W2019042812 @default.
• W4232181540 cites W2020876082 @default.
• W4232181540 cites W2028733942 @default.
• W4232181540 cites W2031388596 @default.
• W4232181540 cites W2035227503 @default.
• W4232181540 cites W2046857998 @default.
• W4232181540 cites W2051108113 @default.
• W4232181540 cites W2054966058 @default.
• W4232181540 cites W2058550328 @default.
• W4232181540 cites W2075026707 @default.
• W4232181540 cites W2076084115 @default.
• W4232181540 cites W2079515918 @default.
• W4232181540 cites W2087027624 @default.
• W4232181540 cites W2107228612 @default.
• W4232181540 cites W2146742008 @default.
• W4232181540 cites W2152472678 @default.
• W4232181540 cites W2161703552 @default.
• W4232181540 cites W2163346654 @default.
• W4232181540 cites W2284323937 @default.
• W4232181540 cites W4297040264 @default.
• W4232181540 doi "https://doi.org/10.1016/s1516-4446(12)70035-1" @default.
• W4232181540 hasPublicationYear "2012" @default.
• W4232181540 type Work @default.
• W4232181540 citedByCount "0" @default.
• W4232181540 crossrefType "journal-article" @default.
• W4232181540 hasAuthorship W4232181540A5002947325 @default.
• W4232181540 hasAuthorship W4232181540A5007102081 @default.
• W4232181540 hasAuthorship W4232181540A5020126544 @default.
• W4232181540 hasAuthorship W4232181540A5057091098 @default.
• W4232181540 hasAuthorship W4232181540A5061548672 @default.
• W4232181540 hasAuthorship W4232181540A5062953785 @default.
• W4232181540 hasAuthorship W4232181540A5067659312 @default.
• W4232181540 hasAuthorship W4232181540A5068399783 @default.
• W4232181540 hasAuthorship W4232181540A5078614945 @default.
• W4232181540 hasAuthorship W4232181540A5081439849 @default.
• W4232181540 hasAuthorship W4232181540A5085928491 @default.
• W4232181540 hasAuthorship W4232181540A5090013116 @default.
• W4232181540 hasBestOaLocation W42321815401 @default.
• W4232181540 hasConcept C118552586 @default.
• W4232181540 hasConcept C126322002 @default.
• W4232181540 hasConcept C134018914 @default.
• W4232181540 hasConcept C147583825 @default.
• W4232181540 hasConcept C2776412080 @default.
• W4232181540 hasConcept C2776619155 @default.
• W4232181540 hasConcept C2776921671 @default.
• W4232181540 hasConcept C2780320433 @default.
• W4232181540 hasConcept C2780494398 @default.
• W4232181540 hasConcept C2780613262 @default.
• W4232181540 hasConcept C511355011 @default.
• W4232181540 hasConcept C71924100 @default.
• W4232181540 hasConceptScore W4232181540C118552586 @default.
• W4232181540 hasConceptScore W4232181540C126322002 @default.
• W4232181540 hasConceptScore W4232181540C134018914 @default.
• W4232181540 hasConceptScore W4232181540C147583825 @default.
• W4232181540 hasConceptScore W4232181540C2776412080 @default.
• W4232181540 hasConceptScore W4232181540C2776619155 @default.
• W4232181540 hasConceptScore W4232181540C2776921671 @default.
• W4232181540 hasConceptScore W4232181540C2780320433 @default.
• W4232181540 hasConceptScore W4232181540C2780494398 @default.
• W4232181540 hasConceptScore W4232181540C2780613262 @default.
• W4232181540 hasConceptScore W4232181540C511355011 @default.
• W4232181540 hasConceptScore W4232181540C71924100 @default.
• W4232181540 hasIssue "2" @default.
• W4232181540 hasLocation W42321815401 @default.
• W4232181540 hasLocation W42321815402 @default.
• W4232181540 hasOpenAccess W4232181540 @default.
• W4232181540 hasPrimaryLocation W42321815401 @default.

• next